Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
improvement in time-to-arise and a 2.7-second improvement in the 10-m walk/run — changes Sarepta characterizes as roughly a ~70% slowing of DMD progression and maintained function at a mean age of ~9. No new safety signals: Sarepta reported no treatment-related serious adverse events in year three and pointed to safety experience from more than 1,200 clinical and commercial exposures. Commercial and data plans: The company intends to emphasize safety and the expanding efficacy dataset in 2026, is doubling its sales force, and will share additional cardiac, respiratory and pipeline readouts later this year, with no label changes decided yet. Interested in Sarepta Therapeutics, Inc.? Here are five stocks we like better. Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ELEVIDYS, highlighting what executives described as the first large, well-contro
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s DiseaseBusiness Wire
- Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]Yahoo! Finance
- Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.MarketBeat
- Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- 1/21/26 - Form SCHEDULE
- SRPT's page on the SEC website